about
Sui generis: gene therapy and delivery systems for the treatment of glioblastomaCellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.Salvia miltiorrhiza extract dihydrotanshinone induces apoptosis and inhibits proliferation of glioma cells.TRIM28 and β-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkersThe future of high-grade glioma: Where we are and where are we going.Gene therapy for malignant glioma.Lentiviral Vector Mediated Claudin1 Silencing Inhibits Epithelial to Mesenchymal Transition in Breast Cancer Cells.Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates.EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMARUNX3 is down-regulated in glioma by Myc-regulated miR-4295Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer.Role of NK cells in immunotherapy and virotherapy of solid tumors.Oncolytic Virotherapy for the Treatment of Malignant Glioma.Future directions of operative neuro-oncology.Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma: why did promise not translate to human therapy?Zika virus has oncolytic activity against glioblastoma stem cells.Oncolytic Viral Therapy for Mesothelioma.Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas.Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.How to get from here to there: tracking down invasive glioma cells.Glioma.Designing and building oncolytic viruses.Glioblastoma under Siege: An Overview of Current Therapeutic Strategies.Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells.
P2860
Q26850467-9A35D919-3363-418C-AEB6-05C093E0F43CQ30395978-2C46CAF1-BD1A-43E1-B5E8-69C04B918C8EQ32177594-723D23D9-D8F0-429A-AFA0-4AC4584AE62FQ34566316-E924EBEE-F32F-4AF5-B0C7-C6D1A9794B50Q35114090-54691890-7119-49DE-A49A-8B471C023549Q35673628-9B184F9A-41B7-48A9-81B0-86513C35CD15Q35808662-125F17EC-E17E-4FCD-ADD3-704405DEC4A4Q36266545-D6CEEA40-DA50-4A51-AE90-91DA1D022D2EQ36370196-093AE2BA-CB6A-4343-A09B-26A1689F1EDBQ36549443-A358D788-9AAC-4077-A36A-F44FE2967B83Q36595241-814BD822-F01D-477B-A752-F730197A7FB8Q36947035-79C63462-CEA3-4EF7-BC60-88F5D4E007F7Q37008504-22D665C5-AD9A-46DB-A108-EBD2A9E310BFQ38575116-6A63028C-C864-4A84-84E2-441396CAE561Q38749871-95E2FADA-65C2-4F36-9CD5-FBAE417BAC66Q38801098-AB43F2CF-82C5-438E-AB55-458C6743D75AQ38924569-01127B29-76E6-4796-A808-E9CF2BFE14ECQ38964404-6060A415-9CEE-4DAC-8FF0-E71A9AA879B6Q40037821-23760513-DD45-41AF-8F19-C059CF459AEDQ40051845-EB6BB095-E9F3-4531-A9AA-6BB525002A89Q40086745-18C37207-C3EF-4564-9052-1B2A9311B054Q40529135-8E36F03E-7EF6-40AD-A2C9-C208E3228DE4Q40982444-BC604110-0FA7-47DF-BA88-E7FA9244FFA8Q41189810-93AAEC0C-9466-4BEA-83B2-E072638A9447Q44119855-6EEBADB0-6CF8-4579-8DB2-690484921279Q46820292-C08EA587-FBF7-42F9-8C89-0D74F1E2D6BBQ47547386-2E2AF3D9-B1F2-4D2F-9137-01CE26609BD2Q47553080-4513E8B5-6EE2-4B56-B0B0-F673D6B2864CQ48769325-0A20BEC7-A536-410E-A58D-65B7078E7A31Q50128059-730FB4B7-5666-4B82-AF1F-C0227BDC6559
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glioma virus therapies between bench and bedside.
@en
Glioma virus therapies between bench and bedside.
@nl
type
label
Glioma virus therapies between bench and bedside.
@en
Glioma virus therapies between bench and bedside.
@nl
prefLabel
Glioma virus therapies between bench and bedside.
@en
Glioma virus therapies between bench and bedside.
@nl
P2860
P356
P1433
P1476
Glioma virus therapies between bench and bedside.
@en
P2093
E Antonio Chiocca
Johanna K Kaufmann
P2860
P304
P356
10.1093/NEUONC/NOT310
P577
2014-01-26T00:00:00Z